UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture

Pain Clinical Trial

— UNPIN  

Official title:

UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture, a Pilot Randomized Control Trial (UNPIN Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05865327
• Other study ID #: 5715
• Status: Recruiting
• Phase: N/A
• Start date: October 23, 2023
• Est. completion date: December 2025

Study information

• Verified date: September 2023
• Source: Sunnybrook Health Sciences Centre
• Contact: Ben Safa, MD
• Phone: 416-480-4864
• Email: ben.safa[@]sunnybrook.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Traumatic rib fractures (i.e., broken ribs caused by a physical injury) are common and very painful. They also often lead to serious complications, more time spent in hospital, and can even lead to death. Even after rib fractures have healed, they can lead to long-term pain and a lower quality of life. A technology called cryoneurolysis, which acts to freeze nerves causing pain using a small tool which can turn very cold, is a promising new way to manage rib fracture pain. This study is a test with a small number of people to see if it is feasible to use this technology for patients with rib fractures. If this is successful, we will recruit more people for a larger study to see if cryoneurolysis, along with standard pain control techniques, is better at stopping pain, compared to just the normal techniques alone. Participants in our study will be asked to rate their pain, and record pain medications that they take for 3 months after their pain procedure.

Description:

More than 100,000 people a year suffer from traumatic rib fractures. Pain from rib fractures impairs the ability to inspire deeply and cough effectively, predisposing patients to severe, potentially life threatening complications and increased healthcare costs. For many patients, this pain can also persist long after the acute injury has healed, delaying recovery and reducing quality of life. Current pain interventions, including multimodal analgesia and local anesthetic-based nerve blocks, are useful, but are limited by a short duration of effectiveness, and/or risk of complications. Cryoneurolysis (CN) is a new method to control pain which acts to freeze intercostal nerves (ICNs) associated with fractured ribs using a handheld device. This freezing action causes neurons to undergo Wallerian degeneration distally from the site of ablation and thus exhibit an extended but reversible block. This study is a single-site, randomized, pilot study to assess the feasibility of recruitment, randomization, and protocol adherence of providing cryoneurolysis for patients with traumatic rib fractures. Secondary data from the pilot trial designed to assess the effectiveness of the intervention (pain scores, opioid usage, etc.) will be included in the analysis of the full trial if feasible. The objective of the full trial is to demonstrate that cryoneurolysis of ICN, in addition to standard analgesic practice, provides superior, prolonged analgesia. Participants (individuals aged 18-85, with 3-8 unilateral traumatic rib fractures) will be randomized 1:1 in blocks of 4, stratified by number of rib fractures (> 4 or ≤4) and the presence/absence of flail segment, to receive the current standard of practice for rib fractures (multimodal analgesia and erector spinae plane (ESP) catheter infusion) with or without the addition of CN. Participants in the standard care group will receive a sham CN procedure to maintain blinding. All participants (both groups) will receive standard of care analgesia. Specifically, an ultrasound-guided ESP catheter will be placed as per standard protocols. 20cc of 0.5% ropivacaine and 1% lidocaine will be injected through the catheter, followed by a basal infusion of 2 cc/hr of 0.2% ropivacaine (to maintain catheter patency) with an on demand patient controlled regional anesthesia (PCRA) dose of 10cc 0.2% ropivacaine available hourly until patient has met criteria for APS discharge or pain is controlled such that PCRA use is < 2 boluses over 12 hrs and NRS < 3 with deep breathing and coughing. Standard multimodal analgesia including Tylenol 1000mg QID, Celebrex 200mg BID (or ketorolac 7.5 QID), Pregabalin 50mg BID, and/or PRN oral hydromorphone (1-4mg) will also be provided. Additional analgesics include intravenous ketamine at a dose of 0.1-0.2 mg/kg/hr of lean body weight in the event of consistent NRS pain scores > 6, and up to 0.05 mg/kg of intravenous midazolam for anxiolysis and 1mcg/kg of intravenous fentanyl for comfort during positioning, as required. Participants will remain in the study for 3 months from the date of the block procedure. They will be followed daily while in hospital and using a pain diary following discharge (weekly pain scores and daily opioid usage). Additionally, follow-ups will be completed at 1h, 24h, 48h, 1 week, 1 month, and 3 months post block procedure.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Aged =18
• Unilateral traumatic rib fractures (3 to 8)
• Candidate for ESP block catheter
• Within 48hrs of admission to hospital

Exclusion Criteria:

• Lack of patient consent; unlikely to comply with follow up
• Unable to use Patient Controlled Regional Analgesia (Ventilated/sedated patients or Moderate to severe traumatic brain injury)
• Chronic pain (opioid use > 30mg oral morphine equivalent per day)
• Substance use disorder
• CrCl < 50
• BMI > 45
• Significant distracting injuries (unreduced long bone fractures, unstable pelvic or spine fractures and patients requiring trauma laparotomy- also preclude positioning for block placement (lateral decubitus or sitting up))
• Contraindications for ESP catheter placement (pre-existing medical/neurological/hematologic diseases, localized infection/trauma at site of intervention, allergy to amide local anesthetics)
• Contraindications to CN (cryoglobulinemia, paroxysmal cold hemoglobinuria, multiple myeloma and cold urticarial).
• Unable to return to Trauma Recovery Clinic (in-person or virtual) at 3 months

Related Conditions & MeSH terms

• Acute Pain
• Chronic Pain
• Flail Chest
• Fractures, Bone
• Pain
• Pain, Acute
• Pain, Chronic
• Rib Fracture Multiple
• Rib Fractures
• Trauma
• Trauma Injury
• Wounds and Injuries

Intervention

Procedure:
• Cryoneurolysis
Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
• Sham Cryoneurolysis
Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.

Locations

Country	Name	City	State
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pain Intensity	As measured using NRS-11, at rest and during deep inspiration	1h and 48h, post block placement, daily in hospital, weekly post discharge and at 1 week follow-up
Primary	Number of participants randomized over an 8 month period	Goal of 3 participants per month for 8 months	Entire pilot study (approximately 8 months)
Primary	Number of participants able to adhere to the protocol	Goal of > 90%	Entire pilot study (approximately 8 months + 3 month follow-up)
Primary	Number of participants able to adhere to the follow-up	Goal of > 90%	3 month follow-up
Primary	Rate of Adverse events	Ensure no adverse events (short or long term) associated with CN	3 month follow-up
Secondary	Pain Severity during deep inspiration 24 hours post ESP catheter placement	Pain measured using Numeric Pain Rating Scale	24 hours post placement of ESP catheter
Secondary	Time to discontinuation of ESP catheter	Based on when patient has met criteria for APS discharge or pain is controlled such that PCRA use is < 2 boluses over 12 hrs and NRS < 3 with deep breathing and coughing	Until ESP catheter removal (usually < 7 days)
Secondary	ESP catheter use	Cumulative volume of local anesthetic solution used via ESP catheter patient controlled reginal analgesia	Until ESP catheter removal (usually < 7 days)
Secondary	Opioid consumption in hospital and after discharge	Determined from medical records (in-hospital) and via a daily pain diary (post-discharge). Calculated in Oral Morphine Equivalents.	Daily for 90 days after block placement
Secondary	Pain Intensity at 1 and 3 months	As measured using Numeric Pain Rating Scale (0-10) , at rest and during deep inspiration	1 and 3 month follow-ups
Secondary	Oxygen requirements	Room air oxygen saturation (SpO2) and requirement for supplementary O2 to maintain SpO2 > 92%	Pre-intervention, post intervention, then daily until discharge
Secondary	Pulmonary Function Testing	FVC	Pre-intervention, post intervention, then daily until discharge
Secondary	Pulmonary Function Testing	FEV1	Pre-intervention, post intervention, then daily until discharge
Secondary	Pulmonary Function Testing	Peak Inspiratory flow	Pre-intervention, post intervention, then daily until discharge
Secondary	Pulmonary Function Testing	Peak Expiratory Flow	Pre-intervention, post intervention, then daily until discharge
Secondary	Length of Stay in hospital	Hospital discharge date	Date of admission to date discharge
Secondary	Length of Stay on acute pain service (APS)	Criteria include on oral meds without continuous regional analgesia or intravenous opioids	Date of admission to date of discharge from acute pain service
Secondary	Time to achieve discharge criteria for isolated chest injury	Criteria include on oral meds without continuous regional analgesia, chest tube out and chest well evacuated (e.g. no evidence of retained hemothorax), and no supplemental O2	Date of admission until discharge criteria met
Secondary	Patient satisfaction	Patient satisfaction assessed using Patients' Global Impression of Change (PGIC) scale	48 post block procedure, and 1 week, 1 month and 3 month follow-ups
Secondary	Incidence of chronic rib fracture pain	As assessed using Brief Pain Inventory (BPI) questionnaire	3 month follow-up
Secondary	Adverse events	Adverse events to be recorded include: local anesthetic complications, catheter related complications (clotting, migration), procedural complications (pneumothorax, bleeding, infection), and neurological disturbances (dysesthesia, hyperalgesia, allodynia) in area of rib fracture	until 3 month follow-up